Mobilizing Primary Care Against the Opioid Crisis in the Post X-Waiver Era.
作者信息
Incze Michael A, Garland Eric L
机构信息
Division of General Internal Medicine, University of Utah, Salt Lake City, USA.
Program for Addiction Research, Clinical Care, Knowledge and Advocacy (PARCKA), Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, USA.
出版信息
J Gen Intern Med. 2023 Dec;38(16):3618-3620. doi: 10.1007/s11606-023-08382-2. Epub 2023 Aug 31.
Abstract
摘要
相似文献
1
Mobilizing Primary Care Against the Opioid Crisis in the Post X-Waiver Era.在后X豁免时代动员初级保健应对阿片类药物危机。
J Gen Intern Med. 2023 Dec;38(16):3618-3620. doi: 10.1007/s11606-023-08382-2. Epub 2023 Aug 31.
2
Removing One Barrier to Opioid Use Disorder Treatment: Is It Enough?消除阿片类药物使用障碍治疗的一个障碍：这足够了吗？
JAMA. 2021 Mar 23;325(12):1147-1148. doi: 10.1001/jama.2021.0958.
3
The Impact of Completing X-Waiver Training and Clinical Addiction Exposure on Internal Medicine Residents Treating Patients With Opioid Use Disorder.完成 X 豁免培训和临床成瘾暴露对内科住院医师治疗阿片类药物使用障碍患者的影响。
Subst Use Addctn J. 2024 Jul;45(3):356-366. doi: 10.1177/29767342231221004. Epub 2024 Jan 7.
4
What the X? Understanding changes in buprenorphine prescribing regulation.什么？了解丁丙诺啡处方规定的变化。
J Am Assoc Nurse Pract. 2024 Mar 1;36(3):147-150. doi: 10.1097/JXX.0000000000000942.
5
Revisiting emergency department use of buprenorphine as a primary analgesic in nonopioid use disorder patients post-X-waiver.重新审视急诊科在非阿片类药物使用障碍患者X豁免后将丁丙诺啡用作主要镇痛药的情况。
Acad Emerg Med. 2023 Dec;30(12):1272-1274. doi: 10.1111/acem.14749. Epub 2023 May 30.
6
The Implementation of a Clinic-Based Opioid Review Board to Address High-Risk Opioid Prescribing in Primary Care.实施基于诊所的阿片类药物审查委员会以解决初级保健中高风险阿片类药物处方问题。
Ann Fam Med. 2021 Nov-Dec;19(6):563. doi: 10.1370/afm.2738.
7
Treating Adolescent Opioid Use Disorder in Primary Care.在初级保健中治疗青少年阿片类物质使用障碍
JAMA Pediatr. 2024 Apr 1;178(4):414-416. doi: 10.1001/jamapediatrics.2023.6493.
8
A practical review of buprenorphine utilization for the emergency physician in the era of decreased prescribing restrictions.在处方限制减少的时代，急诊医师实用的丁丙诺啡使用回顾。
Am J Emerg Med. 2021 Oct;48:316-322. doi: 10.1016/j.ajem.2021.06.065. Epub 2021 Jul 5.
9
Evaluating buprenorphine prescribing and opioid-related health outcomes following the expansion the buprenorphine waiver program.评估丁丙诺啡处方和阿片类药物相关健康结果后扩大丁丙诺啡豁免计划。
J Subst Abuse Treat. 2022 Jan;132:108452. doi: 10.1016/j.jsat.2021.108452. Epub 2021 Apr 30.
10
Use and misuse of opioid agonists in opioid addiction.阿片类药物成瘾中阿片类激动剂的使用和滥用。
Cleve Clin J Med. 2017 May;84(5):377-384. doi: 10.3949/ccjm.84a.16091.
引用本文的文献
1
Association of economic and racial segregation with restricted buprenorphine dispensing in U.S. community pharmacies.美国社区药房中经济和种族隔离与丁丙诺啡配药受限的关联。
Drug Alcohol Depend Rep. 2024 Jul 14;12:100255. doi: 10.1016/j.dadr.2024.100255. eCollection 2024 Sep.
本文引用的文献
1
Examining the Primary Care Experience of Patients With Opioid Use Disorder: A Qualitative Study.考察患有阿片类药物使用障碍患者的初级保健体验：一项定性研究。
J Addict Med. 2023;17(4):401-406. doi: 10.1097/ADM.0000000000001140. Epub 2023 Jan 25.
2
Differences in buprenorphine treatment quality across physician provider specialties.不同医生专业提供的丁丙诺啡治疗质量存在差异。
Drug Alcohol Depend. 2022 Aug 1;237:109510. doi: 10.1016/j.drugalcdep.2022.109510. Epub 2022 May 23.
3
Changes in US Clinician Waivers to Prescribe Buprenorphine Management for Opioid Use Disorder During the COVID-19 Pandemic and After Relaxation of Training Requirements.《COVID-19 大流行期间及培训要求放宽后美国临床医生开具丁丙诺啡管理阿片类药物使用障碍的豁免权变化》
JAMA Netw Open. 2022 May 2;5(5):e225996. doi: 10.1001/jamanetworkopen.2022.5996.
4
Mindfulness-Oriented Recovery Enhancement vs Supportive Group Therapy for Co-occurring Opioid Misuse and Chronic Pain in Primary Care: A Randomized Clinical Trial.正念导向康复强化治疗与支持性团体心理治疗对初级保健中并存阿片类药物滥用和慢性疼痛的随机临床试验。
JAMA Intern Med. 2022 Apr 1;182(4):407-417. doi: 10.1001/jamainternmed.2022.0033.
5
Contingency Management for Patients Receiving Medication for Opioid Use Disorder: A Systematic Review and Meta-analysis.接受阿片类药物使用障碍药物治疗的患者的应急管理：系统评价和荟萃分析。
JAMA Psychiatry. 2021 Oct 1;78(10):1092-1102. doi: 10.1001/jamapsychiatry.2021.1969.
6
A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder.一种混合方法比较了医生对阿片类药物使用障碍药物治疗的信念和障碍的报告。
Subst Abuse Treat Prev Policy. 2020 Sep 14;15(1):69. doi: 10.1186/s13011-020-00312-3.
7
Stigma in health facilities: why it matters and how we can change it.卫生机构中的污名：为什么它很重要以及我们如何改变它。
BMC Med. 2019 Feb 15;17(1):25. doi: 10.1186/s12916-019-1256-2.
Zotero 插件